BACKGROUND: Chronic hepatitis C (HCV) infection is associated with diabetes and favourable lipids. OBJECTIVE: To study the effect of this paradox on atherosclerosis and cardiometabolic response to HCV clearance. DESIGN: Cross-sectional study. SETTING: Egypt. PARTICIPANTS: 329 chronically infected, 173 with cleared infection and 795 never infected participants aged >or=35 attended for baseline investigations. A subsample of 192, 115 and 187, respectively, underwent ultrasound. MAIN OUTCOME MEASURES: Diabetes, fasting glucose, lipids and fat deposition on ultrasound. Carotid intima-media thickness (IMT) measured atherosclerosis. RESULTS: Diabetes prevalence was raised (10.1% (95% CI 6.6 to 13.6), p=0.04) in HCV chronic, and cleared (10.1% (5.6 to 14.8), p=0.08) individuals versus 6.6% (4.9 to 8.3) in those never infected. Mesenteric fat was raised in chronic (36.4 mm (34.5 to 38.2), p=0.004), and cleared infection (37.8 (35.6 to 40.0), p<0.0001) vs never infected (32.7 (31.0 to 34.4)). LDL cholesterol was lower in chronic (2.69 mmol/l (2.53 to 2.86), p<0.001), but similar in cleared (3.56 (3.34 to 3.78), p=0.4) versus never infected (3.45 (3.30 to 3.60)). Carotid IMT did not differ by infection status: 0.73 (0.70 to 0.76, p=0.4), 0.71 (0.66 to 0.75, p=0.9), 0.71 (0.68 to 0.74), respectively. Adjustment for cardiovascular risk factors increased IMT in chronic infection (0.76 (0.72 to 0.79), p=0.02) versus never infected individuals (0.70 (0.67 to 0.73)). CONCLUSIONS: Hepatic function normalisation with HCV clearance may account for reversal of favourable lipids observed with HCV infection. Hyperglycaemia and visceral adiposity appear less amenable to HCV resolution. These different cardiovascular risk patterns may determine equivalent atherosclerosis risk by infection status. However, once these factors were accounted for, those with chronic infection had raised IMT, suggesting a direct effect of infection.
BACKGROUND:Chronic hepatitis C (HCV) infection is associated with diabetes and favourable lipids. OBJECTIVE: To study the effect of this paradox on atherosclerosis and cardiometabolic response to HCV clearance. DESIGN: Cross-sectional study. SETTING: Egypt. PARTICIPANTS: 329 chronically infected, 173 with cleared infection and 795 never infected participants aged >or=35 attended for baseline investigations. A subsample of 192, 115 and 187, respectively, underwent ultrasound. MAIN OUTCOME MEASURES: Diabetes, fasting glucose, lipids and fat deposition on ultrasound. Carotid intima-media thickness (IMT) measured atherosclerosis. RESULTS:Diabetes prevalence was raised (10.1% (95% CI 6.6 to 13.6), p=0.04) in HCV chronic, and cleared (10.1% (5.6 to 14.8), p=0.08) individuals versus 6.6% (4.9 to 8.3) in those never infected. Mesenteric fat was raised in chronic (36.4 mm (34.5 to 38.2), p=0.004), and cleared infection (37.8 (35.6 to 40.0), p<0.0001) vs never infected (32.7 (31.0 to 34.4)). LDL cholesterol was lower in chronic (2.69 mmol/l (2.53 to 2.86), p<0.001), but similar in cleared (3.56 (3.34 to 3.78), p=0.4) versus never infected (3.45 (3.30 to 3.60)). Carotid IMT did not differ by infection status: 0.73 (0.70 to 0.76, p=0.4), 0.71 (0.66 to 0.75, p=0.9), 0.71 (0.68 to 0.74), respectively. Adjustment for cardiovascular risk factors increased IMT in chronic infection (0.76 (0.72 to 0.79), p=0.02) versus never infected individuals (0.70 (0.67 to 0.73)). CONCLUSIONS: Hepatic function normalisation with HCV clearance may account for reversal of favourable lipids observed with HCV infection. Hyperglycaemia and visceral adiposity appear less amenable to HCV resolution. These different cardiovascular risk patterns may determine equivalent atherosclerosis risk by infection status. However, once these factors were accounted for, those with chronic infection had raised IMT, suggesting a direct effect of infection.
Authors: Umberto Vespasiani-Gentilucci; Paolo Gallo; Antonio De Vincentis; Giovanni Galati; Antonio Picardi Journal: World J Gastroenterol Date: 2014-03-21 Impact factor: 5.742
Authors: Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi Journal: World J Hepatol Date: 2013-10-27
Authors: Man C Wong; Janna A van Diepen; Lihui Hu; Bruno Guigas; Hetty C de Boer; Gijs H van Puijvelde; Johan Kuiper; Anton J van Zonneveld; Steven E Shoelson; Peter J Voshol; Johannes A Romijn; Louis M Havekes; Jouke T Tamsma; Patrick C N Rensen; Pieter S Hiemstra; Jimmy F P Berbée Journal: Atherosclerosis Date: 2011-07-12 Impact factor: 5.162
Authors: Alison L Bailey; Saif Al-Adwan; Eliea Sneij; Nicholas Campbell; Matthew E Wiisanen Journal: Curr Cardiol Rep Date: 2021-04-06 Impact factor: 2.931
Authors: Angela Sciacqua; Maria Perticone; Eliezer J Tassone; Antonio Cimellaro; Benedetto Caroleo; Sofia Miceli; Michele Andreucci; Anna Licata; Giorgio Sesti; Francesco Perticone Journal: Intern Emerg Med Date: 2015-11-23 Impact factor: 3.397